Rgenix has named ex-Novartis staffer Roger Waltzman, M.D., as its chief medical officer.

Shares in U.K. biotech Synairgen were pummeled today as partner AstraZeneca revealed it was stopping development of its inhaled interferon beta therapy AZD9412.

Back in 2014, Roche spent $725 million upfront on California’s Seragon, but three years down the line, it has now canned work on its leading drug, ARN-810.

The Spanish government has ratcheted up the pressure on the European Council to make a quick decision on the new home of the region’s drug regulator.

Amid new approvals last year, drugmakers also suffered R&D setbacks, cut research staff, rejigged their operations and refocused their pipelines.

French pharma Onxeo is teaming up with CRO Clinigen to bring blood cancer med belinostat to European patients in dire need through a managed access program.

Intuitive Surgical has bagged a CE mark for the latest product in its da Vinci series of robot-assisted surgical systems.

Infectious disease specialist Arsanis has raised a solid chunk of cash as it picks up the Gates Foundation and Alphabet's GV as backers.

The Medicines Company and RNA biotech partner Alnylam have set out a new, large late-stage test for their next-gen anticholesterol candidate inclisiran, which…